Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIGROUP INCC · Entity 2837 | Director | January 18, 2011 | January 20, 2011 |
| DuPont de Nemours, Inc.DWDP · Entity 3297 | Former Executive Chairman | June 11, 2018 | June 13, 2018 |
| INTERNATIONAL BUSINESS MACHINES CORPIBM · Entity 2840 | Director | September 30, 2026 | October 02, 2026 |
| Lucid Group, Inc.LCID · Entity 1530 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIGROUP INC
Report date January 18, 2011 · Filed January 20, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,923.7 |
Reported balance
After 2011-01-18 transaction · row 1
1 source rowRow 1 · 2011-01-18 · Grant · Acquired 29,880.4 · Balance 106,923.7 F1: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,828.7 |
Reported balance
Holding disclosure · report date 2011-01-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,828.7 F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectBy Children | 1,200 |
Reported balance
Holding disclosure · report date 2011-01-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,200 |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors.
F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors.
DuPont de Nemours, Inc.
Report date June 11, 2018 · Filed June 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 387,618.089 |
Ending reported balance
After 2018-06-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-06-11 · Exercise / conversion · Acquired 73,902 · Balance 461,520.089 Row 2 · 2018-06-11 · Sale · Disposed 73,902 · Balance 387,618.089 F1: The number of shares are aggregated for sales occurring within a $1.00 price range on the same date. Reporting Person agrees to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The price represents the weighted average sale price. All sales occurred at a range of $69.55 to $69.60. Row 3 · 2018-06-12 · Exercise / conversion · Acquired 26,098 · Balance 413,716.089 Row 4 · 2018-06-12 · Sale · Disposed 26,098 · Balance 387,618.089 F1: The number of shares are aggregated for sales occurring within a $1.00 price range on the same date. Reporting Person agrees to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: The price represents the weighted average sale price. All sales occurred at a range of $69.55 to $69.65. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2019-02-13 | Direct | 366,792 |
Reported balance
After 2018-06-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-06-11 · Exercise / conversion · Disposed 73,902 · Balance 366,792 F4: Granted under The Dow Chemical Company Amended and Restated 1988 Award and Option Plan. The Plan provides for tax withholding rights. F5: The options vested in three annual installments beginning on February 13, 2010. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2019-02-13 | Direct | 340,694 |
Reported balance
After 2018-06-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-06-12 · Exercise / conversion · Disposed 26,098 · Balance 340,694 F4: Granted under The Dow Chemical Company Amended and Restated 1988 Award and Option Plan. The Plan provides for tax withholding rights. F5: The options vested in three annual installments beginning on February 13, 2010. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,783.2855 |
Reported balance
Holding disclosure · report date 2018-06-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,783.2855 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan ESOP | 4,071.1138 |
Reported balance
Holding disclosure · report date 2018-06-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,071.1138 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 799,273.5 |
Reported balance
Holding disclosure · report date 2018-06-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 799,273.5 |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares are aggregated for sales occurring within a $1.00 price range on the same date. Reporting Person agrees to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: The price represents the weighted average sale price. All sales occurred at a range of $69.55 to $69.60.
F3: The price represents the weighted average sale price. All sales occurred at a range of $69.55 to $69.65.
F4: Granted under The Dow Chemical Company Amended and Restated 1988 Award and Option Plan. The Plan provides for tax withholding rights.
F5: The options vested in three annual installments beginning on February 13, 2010.
INTERNATIONAL BUSINESS MACHINES CORP
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promised Fee ShareSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 45,262 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 444 · Balance 45,262 F1: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. |
Filing footnotes · ownership attribution and instrument terms
F1: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash.
F2: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan.
F3: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement.
Lucid Group, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 126,364 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Grant · Acquired 43,870 · Balance 123,765 F1: These restricted stock units ("RSUs") will vest in full on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of stockholders held after the date of grant, in each case, subject to the reporting person's continued service on the board of directors through the applicable vesting date. The RSUs are also subject to a deferral election by the reporting person and shares will not be issued until the designated deferred settlement date. F2: RSUs are settled in shares of Class A Common Stock on a one-for-one basis. Row 2 · 2026-06-04 · Grant · Acquired 2,599 · Balance 126,364 F3: These RSUs vest in full on the date of the grant in connection with past service. F2: RSUs are settled in shares of Class A Common Stock on a one-for-one basis. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Liveris Capital Partners LLC | 40,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,000 F4: Interests shown consist of 40,000 shares of Class A Common Stock (the "Liveris Capital Shares") beneficially owned by Liveris Capital Partners LLC ("Liveris Capital"). The reporting person has investment control over Liveris Capital and disclaims beneficial ownership of the Liveris Capital Shares. The Liveris Capital Shares were received as part of a distribution from Churchill Sponsor IV LLC applying equally to all securities of a class in January 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") will vest in full on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of stockholders held after the date of grant, in each case, subject to the reporting person's continued service on the board of directors through the applicable vesting date. The RSUs are also subject to a deferral election by the reporting person and shares will not be issued until the designated deferred settlement date.
F2: RSUs are settled in shares of Class A Common Stock on a one-for-one basis.
F3: These RSUs vest in full on the date of the grant in connection with past service.
F4: Interests shown consist of 40,000 shares of Class A Common Stock (the "Liveris Capital Shares") beneficially owned by Liveris Capital Partners LLC ("Liveris Capital"). The reporting person has investment control over Liveris Capital and disclaims beneficial ownership of the Liveris Capital Shares. The Liveris Capital Shares were received as part of a distribution from Churchill Sponsor IV LLC applying equally to all securities of a class in January 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DOW CHEMICAL CO /DE/
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 1
1 source rowRow 1 · 2017-08-31 · Disposition to issuer · Disposed 215,849.089 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F2: Includes 61,190 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 13, 2018 as DowDuPont Common Stock, 66,750 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 12, 2019 as DowDuPont Common Stock and 51,890 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 10, 2020 as DowDuPont Common Stock, in each case, contingent upon continued employment. |
| CommonSEC Table I · non-derivative | IndirectBy 401(k) Plan | 0 |
Reported balance
After 2017-08-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-08-31 · Disposition to issuer · Disposed 1,686.7065 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. |
| CommonSEC Table I · non-derivative | IndirectBy 401(k) Plan ESOP | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 3,673.8586 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. |
| CommonSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2017-08-31 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-08-31 · Disposition to issuer · Disposed 821,324.5 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.00 · Expires 2022-02-10 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-31 · Disposition to issuer · Disposed 516,000 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.19 · Expires 2027-02-10 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-31 · Disposition to issuer · Disposed 263,860 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F5: This option, which would have vested in three equal installments beginning on February 10, 2018, was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont Common Stock for $61.19 per share on the same vesting terms. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.38 · Expires 2021-02-11 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-08-31 · Disposition to issuer · Disposed 412,380 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.79 · Expires 2020-02-12 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-08-31 · Disposition to issuer · Disposed 551,800 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.01 · Expires 2026-02-12 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-08-31 · Disposition to issuer · Disposed 331,510 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $46.01 per share, with the remaining two-thirds of the option vesting in two equal installments on February 12, 2018 and February 12, 2019. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2019-02-13 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-08-31 · Disposition to issuer · Disposed 909,100 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.44 · Expires 2025-02-13 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-08-31 · Disposition to issuer · Disposed 312,670 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F7: Two-thirds of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $49.44 per share, with the remaining one-third of the option vesting on February 13, 2018. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.71 · Expires 2024-02-14 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-08-31 · Disposition to issuer · Disposed 315,930 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.62 · Expires 2018-02-15 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-08-31 · Disposition to issuer · Disposed 619,370 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2023-02-15 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-08-31 · Disposition to issuer · Disposed 761,660 · Balance 0 F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3: This option was fully vested and exercisable at the time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18.
F2: Includes 61,190 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 13, 2018 as DowDuPont Common Stock, 66,750 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 12, 2019 as DowDuPont Common Stock and 51,890 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 10, 2020 as DowDuPont Common Stock, in each case, contingent upon continued employment.
F3: This option was fully vested and exercisable at the time of the Merger.
F4: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option.
F5: This option, which would have vested in three equal installments beginning on February 10, 2018, was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont Common Stock for $61.19 per share on the same vesting terms.
F6: One-third of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $46.01 per share, with the remaining two-thirds of the option vesting in two equal installments on February 12, 2018 and February 12, 2019.
F7: Two-thirds of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $49.44 per share, with the remaining one-third of the option vesting on February 13, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2017 Filed Dec 1, 2017 13:44 UTC | DuPont de Nemours, Inc. DWDP · Entity 3297 | Exercise / conversionCommon Stock | 100,551 | $38.62 | $3,883,279.62 |
DisclosureSEC source: 0001225208-17-017923 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,487.089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 13:31 UTC | DuPont de Nemours, Inc. DWDP · Entity 3297 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 49,449 | $38.62 Strike: $38.62 | $1,909,720.38 |
DisclosureSEC source: 0001225208-17-017658 · doc4.xml · derivative · entry 6 LIVERIS ANDREW N · CIK 0001269971 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,921 Underlying: Common Stock · 49,449 shares Expires 2018-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Granted under The Dow Chemical Company Amended and Restated 1988 Award and Option Plan. The Plan provides for tax withholding rights. F4 · derivative.exercise_date: The options vested in three annual installments beginning on February 15, 2009. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 13:31 UTC | DuPont de Nemours, Inc. DWDP · Entity 3297 | SaleCommon Stock | 49,449 | $71.63 | $3,542,185.16 |
DisclosureSEC source: 0001225208-17-017658 · doc4.xml · nonDerivative · entry 2 LIVERIS ANDREW N · CIK 0001269971 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,936.089 F1 · shares: The number of shares are aggregated for sales occurring within a $1.00 price range on the same date. Reporting Person agrees to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · price: The price represents the weighted average sale price. All sales occurred at a range of $71.60 to $71.72. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 13:31 UTC | DuPont de Nemours, Inc. DWDP · Entity 3297 | Exercise / conversionCommon Stock | 49,449 | $38.62 | $1,909,720.38 |
DisclosureSEC source: 0001225208-17-017658 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,385.089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:52 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 517 | $145.08 Strike: $0.00 | $75,006.36 |
DisclosureSEC source: 0001562180-17-003073 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,643 Underlying: Common Stock · 517 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 761,660 | Not disclosed Strike: $32.16 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 14 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 761,660 shares Expires 2023-02-15 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 619,370 | Not disclosed Strike: $38.62 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 13 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 619,370 shares Expires 2018-02-15 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 315,930 | Not disclosed Strike: $46.71 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 12 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 315,930 shares Expires 2024-02-14 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 312,670 | Not disclosed Strike: $49.44 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 11 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 312,670 shares Expires 2025-02-13 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F7 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $49.44 per share, with the remaining one-third of the option vesting on February 13, 2018. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 909,100 | Not disclosed Strike: $9.53 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 10 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 909,100 shares Expires 2019-02-13 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 331,510 | Not disclosed Strike: $46.01 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 9 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 331,510 shares Expires 2026-02-12 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont common stock for $46.01 per share, with the remaining two-thirds of the option vesting in two equal installments on February 12, 2018 and February 12, 2019. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 551,800 | Not disclosed Strike: $27.79 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 8 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 551,800 shares Expires 2020-02-12 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 412,380 | Not disclosed Strike: $38.38 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 7 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 412,380 shares Expires 2021-02-11 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 263,860 | Not disclosed Strike: $61.19 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 6 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 263,860 shares Expires 2027-02-10 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F5 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 10, 2018, was assumed by DowDuPont in the Merger and converted into an option to purchase an equal number of shares of DowDuPont Common Stock for $61.19 per share on the same vesting terms. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 516,000 | Not disclosed Strike: $34.00 | Not disclosed |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · derivative · entry 5 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 516,000 shares Expires 2022-02-10 F4 · price: In accordance with the terms of the Merger Agreement, each stock option of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of DowDuPont common stock equal to the total number of shares of Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of the Issuer's option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 821,324.5 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · nonDerivative · entry 4 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 3,673.8586 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · nonDerivative · entry 3 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan ESOP Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 1,686.7065 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · nonDerivative · entry 2 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:08 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 215,849.089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014594 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F2 · shares: Includes 61,190 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 13, 2018 as DowDuPont Common Stock, 66,750 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 12, 2019 as DowDuPont Common Stock and 51,890 deferred shares that, as a result of the Merger and pursuant to the Merger Agreement, were assumed by DowDuPont and will be delivered on or about February 10, 2020 as DowDuPont Common Stock, in each case, contingent upon continued employment. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:43 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 488 | $153.83 Strike: $0.00 | $75,069.04 |
DisclosureSEC source: 0001562180-17-002401 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,992 Underlying: Common Stock · 488 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 19:44 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 431 | $174.14 Strike: $0.00 | $75,054.34 |
DisclosureSEC source: 0001562180-17-001380 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,385 Underlying: Common Stock · 431 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 21:18 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Tax withholdingCommon | 27,751 | $61.72 | $1,712,791.72 |
DisclosureSEC source: 0001225208-17-003574 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,849.081 F1 · kind: Shares withheld pursuant to tax withholding rights under award and option plans in a transaction exempt under Rule 16b-3. F2 · shares: Stock withheld on the delivery date to cover taxes for deferred stock granted on February 14, 2014, as previously reported. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 21:16 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 263,860 | $0.00 Strike: $61.19 | $0.00 |
DisclosureSEC source: 0001225208-17-003213 · doc4.xml · derivative · entry 5 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,860 Underlying: Common · 263,860 shares Expires 2027-02-10 F1 · security: Granted under The Dow Chemical Company 2012 Stock Incentive Plan. The Plan provides for tax withholding rights. F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 10, 2018. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 21:16 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GrantCommon | 51,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003213 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,600.081 F1 · security: Granted under The Dow Chemical Company 2012 Stock Incentive Plan. The Plan provides for tax withholding rights. F2 · shares: Deferred shares to be delivered in one installment on or about February 10, 2020 contingent upon continuation of employment. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:11 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GiftCommon | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-002979 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 817,480.5 F1 · balance_after: Amount of securities beneficially owned reflects a change in form of ownership of 74,181 shares from direct holdings to the Reporting Person's trust. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:20 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $43.59 | $0.00 |
DisclosureSEC source: 0001225208-17-002177 · doc4.xml · derivative · entry 7 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 460,000 shares Expires 2017-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Granted under The Dow Chemical Company 1988 Award and Option Plan. The Plan provides for tax withholding rights. F3 · derivative.exercise_date: The options vested in three equal annual installments beginning on February 16, 2008. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:20 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Tax withholdingCommon | 326,172 | $61.48 | $20,051,423.70 |
DisclosureSEC source: 0001225208-17-002177 · doc4.xml · nonDerivative · entry 3 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,891.081 Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:20 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Tax withholdingCommon | 59,647 | $61.48 | $3,666,799.33 |
DisclosureSEC source: 0001225208-17-002177 · doc4.xml · nonDerivative · entry 2 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,063.081 F1 · kind: Shares withheld pursuant to tax withholding rights under award and option plans in a transaction exempt under Rule 16b-3. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:20 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Exercise / conversionCommon | 460,000 | $43.59 | $20,051,400.00 |
DisclosureSEC source: 0001225208-17-002177 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,710.081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:22 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 452 | $165.99 Strike: $0.00 | $75,027.48 |
DisclosureSEC source: 0001562180-17-000051 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,861 Underlying: Common Stock · 452 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 21:28 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GiftCommon | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-042507 · doc4.xml · nonDerivative · entry 2 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 744,299.5 F2 · shares: These shares were gifted to a charitable foundation that is controlled by the reporting person and his spouse. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:28 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GiftCommon | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-042507 · doc4.xml · nonDerivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 799,299.5 F1 · shares: These shares were gifted in a charitable transaction. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 23:54 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 473 | $158.85 Strike: $0.00 | $75,136.05 |
DisclosureSEC source: 0001562180-16-003183 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,313 Underlying: Common Stock · 473 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| June 30, 2016 Filed Jul 1, 2016 19:21 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 495 | $151.78 Strike: $0.00 | $75,131.10 |
DisclosureSEC source: 0001562180-16-002738 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,746 Underlying: Common Stock · 495 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 20:06 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 496 | $151.45 Strike: $0.00 | $75,119.20 |
DisclosureSEC source: 0001562180-16-002037 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,158 Underlying: Common Stock · 496 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| December 31, 2015 Filed Jan 4, 2016 22:33 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 545 | $137.62 Strike: $0.00 | $75,002.90 |
DisclosureSEC source: 0001562180-16-001170 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,574 Underlying: Common Stock · 545 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| September 30, 2015 Filed Oct 1, 2015 17:25 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 518 | $144.97 Strike: $0.00 | $75,094.46 |
DisclosureSEC source: 0001562180-15-000822 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 Underlying: Common Stock · 518 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| June 30, 2015 Filed Jul 1, 2015 17:43 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 462 | $162.66 Strike: $0.00 | $75,148.92 |
DisclosureSEC source: 0001562180-15-000543 · primarydocument.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 462 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| March 31, 2015 Filed Apr 1, 2015 17:45 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 468 | $160.50 Strike: $0.00 | $75,114.00 |
DisclosureSEC source: 0001181431-15-005349 · rrd424055.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,831 Underlying: Common Stock · 468 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| December 31, 2014 Filed Jan 2, 2015 18:07 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 390 | $160.44 Strike: $0.00 | $62,571.60 |
DisclosureSEC source: 0001181431-15-000009 · rrd420943.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,313 Underlying: Common Stock · 390 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 18:50 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 330 | $189.83 Strike: $0.00 | $62,643.90 |
DisclosureSEC source: 0001181431-14-032906 · rrd416934.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 330 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| June 30, 2014 Filed Jul 1, 2014 23:06 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 345 | $181.27 Strike: $0.00 | $62,538.15 |
DisclosureSEC source: 0001181431-14-025578 · rrd412649.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,510 Underlying: Common Stock · 345 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| March 31, 2014 Filed Apr 1, 2014 17:34 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 325 | $192.49 Strike: $0.00 | $62,559.25 |
DisclosureSEC source: 0001181431-14-014663 · rrd406713.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,129 Underlying: Common Stock · 325 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| December 31, 2013 Filed Jan 2, 2014 16:40 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 335 | $187.05 Strike: $0.00 | $62,660.08 |
DisclosureSEC source: 0001181431-14-000047 · rrd398709.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,774 Underlying: Common Stock · 335 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| September 30, 2013 Filed Oct 1, 2013 20:32 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 337 | $185.56 Strike: $0.00 | $62,533.72 |
DisclosureSEC source: 0001181431-13-051469 · rrd391762.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,411 Underlying: Common Stock · 337 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| June 30, 2013 Filed Jul 1, 2013 17:01 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 329 | $190.54 Strike: $0.00 | $62,686.02 |
DisclosureSEC source: 0001181431-13-037373 · rrd384820.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,049 Underlying: Common Stock · 329 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| March 31, 2013 Filed Apr 1, 2013 15:07 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 296 | $211.59 Strike: $0.00 | $62,630.64 |
DisclosureSEC source: 0001181431-13-019529 · rrd375590.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,699 Underlying: Common Stock · 296 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| December 31, 2012 Filed Jan 2, 2013 16:07 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 329 | $190.27 Strike: $0.00 | $62,598.83 |
DisclosureSEC source: 0001181431-13-000064 · rrd365233.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386 Underlying: Common Stock · 329 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| September 30, 2012 Filed Oct 1, 2012 18:40 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 303 | $206.82 Strike: $0.00 | $62,664.95 |
DisclosureSEC source: 0001181431-12-052448 · rrd357160.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040 Underlying: Common Stock · 303 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
| June 30, 2012 Filed Jul 2, 2012 17:06 UTC | INTERNATIONAL BUSINESS MACHINES CORP IBM · Entity 2840 | GrantPromised Fee Share · Derivative | 322 | $194.12 Strike: $0.00 | $62,506.64 |
DisclosureSEC source: 0001181431-12-038680 · rrd350063.xml · derivative · entry 1 LIVERIS ANDREW N · CIK 0001269971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,722 Underlying: Common Stock · 322 shares Expires not disclosed F1 · derivative.exercise_price: Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan are paid out after retirement in the company's common stock or cash. F2 · kind: Deferral of fees into Promised Fee Shares under the terms of the IBM Board of Directors Deferred Compensation and Equity Award Plan. F3 · derivative.exercise_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. F3 · derivative.expiration_date: Distribution of Promised Fee Shares under the IBM Board of Directors Deferred Compensation and Equity Award Plan is deferred until retirement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.